drugset / Trial / NCT01665417

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

NCT01665417

Phase 4 Unknown 100 enrolled Betta Pharmaceuticals Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to compare the efficacy and safety of first-line icotinib treatment and first-line chemotherapy followed by maintenance treatment with icotinib.

Timeline

Start
2012-08
Primary completion
2017-07
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2
Subject Docetaxel Small molecule 75 mg/m2
Subject Icotinib Small molecule 125 mg Oral
Subject Oxaliplatin Small molecule 500 mg/m2